Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting 18.04.2023 / 17:30 CET/CEST Press Release (PDF) The shareholders approved, among others:
Reinach, 18 April 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, today held its Annual General Meeting (AGM) in Basel. Shareholders approved all proposals put forward by the Board of Directors by a large majority. Stephan Schindler, newly elected Chairperson of Evolva, stated: “We thank our shareholders for their ongoing support and trust as expressed by their approval of all suggested agenda items by a large majority. Together with my colleagues on the Board and in close collaboration with our CEO Christian Wichert and his team, we strive to build on the solid foundation which the new leadership team has been able to lay over the past 12 months and to further accelerate the profitable growth of Evolva to deliver long-term value to our shareholders.” The shareholders approved the following proposals of the Board:
Documentation The Invitation to the AGM 2023 with all proposed agenda items is available on the company’s website under this [Link]. The minutes of the AGM will be posted on the AGM page within one week [Link].
Important dates 24 August 2023 Half-year 2023 results
Contact Doris Rudischhauser Head of Investor Relations and Corporate Communications +41 79 410 81 88
About Evolva Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to wellness, health and sustainability. Find out more at evolva.com and connect with us on LinkedIn. For Evolva multimedia content, please visit: evolva.com/multimedia-library.
Disclaimer This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
End of Media Release |
Language: | English |
Company: | Evolva Holding SA |
Duggingerstrasse 23 | |
4153 Reinach | |
Switzerland | |
Phone: | +41 61 485 20 00 |
Internet: | www.evolva.com |
ISIN: | CH0021218067 |
Valor: | 2121806 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1610833 |
End of News | EQS News Service |
|
1610833 18.04.2023 CET/CEST